Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Observational 4Interventional 3

Sponsor

Cancer Type

Gastrointestinal 27Genitourinary 16Thoracic 14Gynecologic 14Other hematologic neoplasm 13Lymphoid 11Head & Neck 10Breast 10CNS 9Dermatologic 7Plasma cell 5Tumor-Agnostic 3Myeloid 3Sarcoma 2Other solid neoplasm 2Endocrine 2Classical hematology 2Other neoplasm 1Other 1

Conditions

Neoplasm Metastasis 3

Interventions

pembrolizumab 94Paclitaxel 85Gemcitabine 83Carboplatin 79Docetaxel 60Cisplatin 58Bevacizumab 58Nivolumab 56Fluorouracil 47Capecitabine 46Magnetic Resonance Spectroscopy 44Radiotherapy 41Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 37Pemetrexed 34Leucovorin 34Biopsy 34atezolizumab 33Cetuximab 32Standard of Care 31Trastuzumab 28Cyclophosphamide 28Blood Specimen Collection 28Radiosurgery 27Specimen Handling 26Sorafenib 26Ipilimumab 26Everolimus 26olaparib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Observation × Tumor-Agnostic × Clear all
NCT06745024 2026-05-04

Comparing Radiation Therapy to Usual Treatment for Patients With High-Risk Bone Metastases That Are Not Causing Pain, PREEMPT Trial

NRG Oncology

Phase 3 Active not recruiting
280 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT05717166 2025-12-31

SABR-SYNC

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Phase 3 Recruiting
180 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT03721341 2025-09-18

SABR-COMET 10

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Phase 3 Active not recruiting
204 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡